A retrospective study finds that bimekizumab yields comparable drug survival to interleukin-23 inhibitors after the failure of interleukin-17 inhibitors in patients with psoriasis.
Medscape News UK
Source link : https://www.medscape.com/viewarticle/can-bimekizumab-match-il-23-inhibitors-drug-survival-after-2026a1000l80?src=rss
Author :
Publish date : 2026-06-25 12:00:00
Copyright for syndicated content belongs to the linked Source.
